NCT06629623View on ClinicalTrials.gov

Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis

Enrolling by invitationOBSERVATIONAL
Enrollment

310

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
OTHER

No intervention

No intervention

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

Zhejiang Chinese Medical University

OTHER_GOV

collaborator

West China Hospital

OTHER

collaborator

Peking University Shenzhen Hospital

OTHER

lead

Chu Hongling

OTHER

NCT06629623 - Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter